Lorlatinib (PF-06463922)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406533

CAS#: 1454846-35-5 (free base)

Description: Lorlatinib, also known as PF-06463922, is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, ALK/ROS1 inhibitor PF-06463922 binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier.

Chemical Structure

Lorlatinib (PF-06463922)
CAS# 1454846-35-5 (free base)

Theoretical Analysis

MedKoo Cat#: 406533
Name: Lorlatinib (PF-06463922)
CAS#: 1454846-35-5 (free base)
Chemical Formula: C21H19FN6O2
Exact Mass: 406.15535
Molecular Weight: 406.41
Elemental Analysis: C, 62.06; H, 4.71; F, 4.67; N, 20.68; O, 7.87

Price and Availability

Size Price Availability Quantity
25.0mg USD 150.0 Same day
50.0mg USD 250.0 Same day
100.0mg USD 450.0 Same day
200.0mg USD 750.0 Same day
500.0mg USD 1450.0 Same day
1.0g USD 2450.0 Same day
2.0g USD 4250.0 Same day
5.0g USD 5650.0 Same day
10.0g USD 8950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 1924207-18-0 (acetate)   2135926-03-1 (maleate)   1454846-35-5 (free base)   2306217-6 (hydrate)    

Synonym: PF06463922; PF 06463922; PF-06463922; PF-6463922; PF6463922; PF 6463922; Lorlatinib; Lorbrena.

IUPAC/Chemical Name: (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile.


InChi Code: InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1

SMILES Code: N#CC1=C(C(CN2C)=NN1C)C3=CN=C(N)C(O[C@H](C)C4=CC(F)=CC=C4C2=O)=C3

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.09.01

Preparing Stock Solutions

The following data is based on the product molecular weight 406.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Patel M, Chen J, McGrory S, O'Gorman M, Nepal S, Ginman K, Pithavala YK. The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants. Invest New Drugs. 2019 Nov 14. doi: 10.1007/s10637-019-00872-7. [Epub ahead of print] Review. PubMed PMID: 31728714.

2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548564/ PubMed PMID: 31643879.

3: Yang J, Gong W. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Expert Rev Clin Pharmacol. 2019 Mar;12(3):173-178. doi: 10.1080/17512433.2019.1570846. Epub 2019 Jan 30. Review. PubMed PMID: 30657349.

4: Syed YY. Lorlatinib: First Global Approval. Drugs. 2019 Jan;79(1):93-98. doi: 10.1007/s40265-018-1041-0. Review. PubMed PMID: 30604291.

5: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK535599/ PubMed PMID: 30601608.

6: Akamine T, Toyokawa G, Tagawa T, Seto T. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. Onco Targets Ther. 2018 Aug 22;11:5093-5101. doi: 10.2147/OTT.S165511. eCollection 2018. Review. PubMed PMID: 30174447; PubMed Central PMCID: PMC6110295.

7: Basit S, Ashraf Z, Lee K, Latif M. First macrocyclic 3(rd)-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib. Eur J Med Chem. 2017 Jul 7;134:348-356. doi: 10.1016/j.ejmech.2017.04.032. Epub 2017 Apr 13. Review. PubMed PMID: 28431340.

Additional Information